References and Notes



1. The Physicians Committee for Responsible Medicine (Washington, D.C.;, the Medical Research Modernization Committee (Cleveland, Ohio;, and Europeans for Medical Progress (London, U.K., combined have over 12,000 physician and scientist members, most of whom are highly critical of animal experimentation.

2. Barnard ND, Kaufman SR. Animal research is wasteful and misleading. Scientific American 1997; Feb: 80-82.

3. Research Defense Society. Medical Advances and Animal Research.

4. Botting JH, Morrison AD. Animal research is vital to medicine. Scientific American 1997; Feb: 83-85.

5. Reines BP. On the locus of medical discovery. Journal of Medicine and Philosophy 1991; 116: 183-209.

6. Reines BP. On the role of clinical anomaly in Harvey's discovery of the mechanism of the pulse. Perspectives in Biology and Medicine 1990; 34: 128-133.

7. McQuarrie I. The Experiments of Nature and Other Essays from the Porter Lectures. Lawrence, Kansas, University of Kansas Press, 1944.

8. Beeson PB. The growth of knowledge about a disease: hepatitis. American Journal of Medicine 1979; 67: 366-370.

9. Good RA. Runestones in immunology. Journal of Immunology 1976; 117:1413-1428.

10. Good RA. Keystones. Journal of Clinical Investigation 1968; 47:1466-1471. [Beeson and Good have emphasized that they consider animal experimentation it important to medical progress. However, their articles demonstrate the primacy of human clinical investigation.]

11. Greek CR, Greek JW. Specious Science. New York, Continuum, 2002.

12. Brecher R. The Consumers Union Report on Smoking and the Public Interest. Mount Vernon, Consumers Union, 1963.

13. Northrup E. Men, mice, and smoking, in Science Looks at Smoking. New York, Coward-McCann, 1957, p 133.

14. Enterline PE. Asbestos and cancer, in Gordis L (ed). Epidemiology & Health Risk Assessment. New York, Oxford University Press, 1988.

15. Gardner MJ, Snee MP, Hall AJ, et al. Results of case-control study of leukaemia and lymphoma among young people near Sellafield nuclear plant in West Cumbria. British Medical Journal 1990; 300:423-429.

16. Stewart A. Alternative sources of risk estimates for cancer effects of radiation. The Mount Sinai Journal of Medicine 1995; 62:380-385.

17. Gould JM, Sternglass EJ. Nuclear fallout, low birthweight, and immune deficiency. International Journal of Health Science 1994; 24:311-335.

18. Bross ID. Fifty Years of Folly and Fraud "In the Name of Science." Buffalo, Biomedical Metatechnology, 1994.

19. Parish HJ. Victory with Vaccines. Edinburgh and London, E&S Livingstone Ltd., 1968.

20. Paul JR. History of Poliomyelitis. New Haven, Yale University Press, 1971.

21. Sabin AB. Statement of Albert B. Sabin, M.D. Hearing before the Subcommittee on Hospitals and Health Care of the Committee on Veterans' Affairs of the House of Representatives, April 26, 1984, serial no. 98-48.

22. Enders JF, Weller TH, Robbins FC. Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissue. Science 1949; 109:85-86.

23. Domingo RT, Fries C, Sawyer P, Wesolowski S. Peripheral arterial reconstruction. Transplantation of autologous veins. Transactions of the American Society of Artificial Internal Organs 1963; 9:305-316.

24. Hume D. Experiences with renal homotransplantation in the human subject. Journal of Clinical Investigation 1955; 34:327-381.

25. Bailar JC III, Gornik HL. Cancer undefeated. New England Journal of Medicine 1997; 336:1569-1574.

26. Dulbecco R. A turning point in cancer research: Sequencing the human genome. Science 1986; 231:1055-1056.

27. Leavitt J. The case for understanding the molecular nature of cancer: Some recent findings and their implications. Medical News Sept 9, 1985.

28. Bross I. Crimes of Official Science. Buffalo, Biomedical Metatechnology, 1987.

29. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999; 400:464-467.

30. Cimons M, Getlin J, Maugh II, TH. Cancer drugs face long road from mice to men. Los Angeles Times, May 6, 1998.

31. Anderson ER, Xiong H, Gendelman HE. Animal Model Systems of HIV-Diseases, in Friedman H, Specter S, Bendinelli M,  In Vivo Models of HIV Disease and Control. Berlin, Springer-Verlag, 2006.

32. Mitsuya H, Weinhold KJ, Furman PA, et al. 3'-Azido-3'deoxythymidine (BS A509U). Proceedings of the National Academy of Sciences USA 1985; 82:7096-7100.

33. Soudeyns H, Yao X-J, Gao Q, et al. Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH 189), a novel heterocyclic nucleoside analog. Antimicrobial Agents and Chemotherapeutics 1991; 35:1386-1390.

34. Roberts NA, Martin JA, Kinchington D, et al. Rational design of peptide-based HIV proteinase inhibitors. Science 1990: 248;358-361.

35. Bailey J. An assessment of the role of chimpanzees in AIDS vaccine research Alternatives to Laboratory Animals 2008; 36:381-428.

36. Esparza J. A brief history of the global effort to develop a preventive HIV vaccine. Vaccine 2013; 31:3502-18.

37. Zbinden G, Flury-Roversi M. Significance of the LD50 test for the toxicological evaluation of chemical substances. Archives of Toxicology 1981; 47:77-99.

38. Fano A. Lethal Laws: Animal Testing, Human Health and Environmental Policy. London, Zed Books, 1997, pp 157-159.

39. Stephens M. Replacing animal experiments, in Langley G (ed). Animal Experimentation: The Consensus Changes. New York, Chapman and Hall, 1989, pp 144-168.

40. Lave LB, Ennever FK, Rosenkranz HS, Omenn GS. Information value of the rodent bioassay. Nature 1988; 336:631-633.

42. Bailey J, Knight A, Balcombe J. The future of teratology research is in vitro. Biogenic Amines, 2005; 19 (2):97-145.

42. Coleman RA. Human-based systems in drug and chemical safety testing – toward replacement, the ‘single R’. Alternatives to Laboratory Animals 2014; 42:357-366.

43. Kenna J G. Human biology-based drug safety evaluation: scientific rationale, current status and future challenges. Expert Opinion on Drug Metabolism and Toxicity 2017; 13:567-574


45. LaFollette H, Shanks N. Animal models in biomedical research: Some epistemological worries. Public Affairs Quarterly 1992; 7:113-130.

46. LaFollette H, Shanks N. Brute Science. New York, Routledge, 1997.

47. Kaufman SR, Reines BP, Casele H, Lawson L, Lurie J. An evaluation of ten randomly chosen animal models of human diseases. Perspectives on Animal Research 1989; 1 (Suppl): 1-128.

48. Kaufman SR, Czarnecki T, Haralabatos I, Richardson M. Animal models of degenerative neurological diseases. Perspectives on Medical Research 1991; 3:9-48.

49. Smith CD. A critique of brain wound research. Perspectives on Animal Research 1989; 1:19-24.

50. Buyukmihci NC. Response to Dr. Blakemore's assertion that work involving nonhuman animals has led to significantly greater understanding and treatment of amblyopia. Perspectives on Animal Research 1989; 1:57-62.

51. Cohen MJ, Black DN, Fouts RS, Dobbs FW. A critique of neurology experiments at Northwestern University. Perspectives on Medical Research 1993; 4:22-28.

52. Kaufman SR. Animal models of spinal cord injury. Perspectives on Medical Research 1990; 2:1-12.

53. Mack JD, Greenberg RA. Review of scoliosis research at the University of Michigan. Perspectives on Medical Research 1990; 2:33-36.

54. Committee on Animal Models in Biomedical Research. Aping Science. Medical Research Modernization Committee, New York, 1995.

55. Bailey J. Monkey-based research on human disease: the implication of genetic differences. Alternatives to Laboratory Animals 2014; 42:287-317.

56. Bailey J. Lessons from chimpanzee-based research on human disease: the implications of genetic differences. Alternatives to Laboratory Animals 2011; 39:527-40.

57. Greek R, Menache A. Systematic Review of Animal Models: Methodology versus Epistemology. International Journal of Medical Sciences 2013; 10:206-221.

58. Peller S. Quantitative Research in Human Biology and Medicine. Bristol, England, John Wright & Sons, 1967.

59. Hewitt HB. The use of animals in experimental cancer research, in Sperlinger D (ed). Animals in Research. New York, John Wiley & Sons, 1981.

60. Freedman DA, Zeisel H. From mouse to man: The quantitative assessment of cancer risks. Statistical Science 1988; 3:3-28.

61. Smith CD. Head injury research at the University of Cincinnati. Perspectives on Animal Research 1989; 1:9-18.

62. Ames BN, Gold LS. Too many rodent carcinogens: Mitogenesis increases mutagenesis. Science 1990; 249:970-971.

63. Wiebers DO, Adams HP, Whisnant JP. Animal models of stroke: Are they relevant to human disease? Stroke 1990; 21:1-3.

64. Habal MB. The influence of lip repair with and without soft-tissue undermining on facial growth in beagles [discussion]. Plastic and Reconstructive Surgery 1988; 82:756-759.

65. Fernandes D. Animal experimentation: Necessary or not? Cleft Palate Journal 1989; 26:258.

66. Sutherland BA, Minnerup J, Balami JS, et al. Neuroprotection for ischaemic stroke: translation from the bench to the bedside. International Journal of Stroke 2021; 7:407-18.

67. Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proceedings of the National Academy of Sciences 2013; 110:3507-12.

68. Mullane K, Williams M. Translational semantics and infrastructure: another search for the emperor’s new clothes? Drug Discovery Today 2012; 17:459-468.

69. Barnard ND, Hou S. Inherent stress: The tough life in lab routine. Lab Animal Sept 1988, pp 21-27.

70. Balcombe JP, Barnard ND, Sandusky C. Laboratory routines cause animal stress. Contemporary Topics 2004; 43: 42-51.

71. Greek CR, Greek JW. Sacred Cows and Golden Geese. New York, Continuum, 2000.

72. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. New England Journal of Medicine 1991; 325:1468-1475.

73. McKenzie R, Fried MW, Sallie R, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. New England Journal of Medicine 1995; 333:1099-1105.

74. Kolata G. 2 top diet drugs are recalled amid reports of heart defects. New York Times Sept 16, 1997, p A1.

75. Couzin J. Estrogen Research: The great estrogen conundrum. Science, 2003; 302:1136-1138.

76. Topol EJ. Failing the public health – Rofecoxib, Merck, and the FDA. New England Journal of Medicine 2004; 351:1707-1709.

77. Bhogal N, Combes R. TGN1412: time to change the paradigm for the testing of new pharmaceuticals. Alternatives to Laboratory Animals 2006; 34:225-239.

78. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. Journal of the American Medical Association 1998; 279:1200-1205.

79. Cohen SM, Ellwein LB. Cell proliferation in carcinogenesis. Science 1990; 249:1007-1011.  80. Factors Affecting Drug Response.

84. Geerts H. Of mice and men: bridging the translational disconnect in CNS drug discovery. CNS Drugs. 2009; 23:915-26.

85. Jankovic J, Noebels JL. Genetic mouse models of essential tremor: are they essential? J Clin Invest. 2005; 115:584-586.

86. Kieburtz K, Olanow CW. Translational experimental therapeutics: The translation of laboratory-based discovery into disease-related therapy. Mt Sinai Journal of Med. 2007; 74:7-14.

87. Liu Z, Maas K, Aune TM. Comparison of differentially expressed genes in T lymphocytes between human autoimmune disease and murine models of autoimmune disease. Clin Immunol. 2004; 112:225-230.

88. Lindle T, Volkel M, Kolar R. [Animal experiments in biomedical research. An evaluation of the clinical relevance of approved animal eperimental projects] (in German) ALTEX 205; 22:143-151.

89. Hackam DG. Translating animal research into clinical benefit: poor methodological standards in animal studies mean that positive results may not translate to the clinical domain. British Medical Journal 2007; 334:163-164.

90. Arrowsmith J. A decade of change. National Review of Drug Discovery 2012; 11:17-18.

91. Hartung T. Food for thought look back in anger – what clinical studies tell us about preclinical work. ALTEX 2013; 30:275-91.

92. U.S. General Accounting Office. FDA Drug Review: Postapproval Risks 1976-1985. Publication GAO/PEMD-90-15, Washington, D.C., 1990.

93. Lifton RJ. The Nazi Doctors. New York, Basic Books, 1986.

94. Barber B. The ethics of experimentation with human subjects. Scientific American 1976; 234(2):25-31.

95. Eilperin J. EPA using data from chemical tests on humans. Washington Post, June 17, 2005, p A03.

96. Cole LA. The Eleventh Plague: The Politics of Biological and Chemical Warfare. New York, W.H. Freeman & Company, 1996.

97. Kiernan V. Radiation doctors abused trust in the name of science. New Scientist Oct 14, 1995, p 8.

98. Annas GJ. Baby Fae: The "anything goes" school of human experimentation. Hastings Center Report 1985; 15(1):15-17.

99. Preston R. The Hot Zone. New York, Random House, 1994.

100. Cohen MJ. Ebola Alice? Texas Republic 1996; 3(2):27-30.

101. McKenna MAJ. Monkey virus kills Yerkes researcher. Atlanta Journal-Constitution Dec 12, 1997.

102. Pennisi E. Monkey virus DNA found in rare human cancers. Science 1997; 275:748-749.

103. Baboon cells fail to combat AIDS. Nature 1996; 379:577.

104. Hooper E. The River: A Journey to the Source of HIV and AIDS. Boston, Little, Brown & Co, 1999.

105. Reinhardt V, Roberts A. The African polio vaccine-acquired immune deficiency syndrome connection. Medical Hypotheses 1997; 48:367-374.

106. Horowitz LG. Emerging Viruses: AIDS and Ebola. Rockport, Mass, Tetrahedron, 1996.

107. Heimlich HJ, Patrick EA. The Heimlich maneuver: Best technique for saving any choking victim's life. Postgraduate Medicine 1990; 87:68-79.

108. Dole VP. On the relevance of animal models to alcoholism in humans. Alcoholism Clinical and Experimental Research 1986; 10:361-363.

109. Cohen MJ, Young C. "Alcoholic" Rats and Other Alcohol Research Using Animals. New York, National Research Information Center, 1989.

110. Sitaram N, Gershon S. Animal models to clinical testing – promises and pitfalls. Progress in Neuropsychopharmacology, Biology and Psychiatry 1983; 7: 227-228.

111. Davis JM. Antipsychotic drugs, in Kaplan HI, Sadock BJ (eds). Comprehensive Textbook of Psychiatry, Fourth Ed. Baltimore, William and Wilkins, 1985.

112. Pearson OH, Eliel LP, Rawson RW, et al. ACTH- and cortisone-induced regression of lymphoid tumors in man. Cancer 1949; 2:943-945.

113. Boesen E. Cytotoxic Drugs in the Treatment of Cancer. London, Edward Arnold, 1969, p 24.

114. Coley WB. A preliminary note on the treatment of inoperable sarcoma by the toxic product of erysipelas. The Post-Graduate 1893; 8:278-286.

115. Caldwell A. Origins of Psychopharmacology: From CPZ to LSD. Springfield, Charles C Thomas, 1970.

116. Lehmann HE, Kline NS. Clinical discoveries with antidepressant drugs, in Parnham MJ, Bruinvels J (eds). Discoveries in Pharmacology, Volume 1. New York, Elsevier, 1983, pp 209-221.

117. Sulser F, Mishra R. The discovery of tricyclic antidepressants and their mode of action, in Parnham MJ, Bruinvels J (eds). Discoveries in Pharmacology, Volume 1. New York, Elsevier, 1983, pp 233-247.

118. Unal B et al. Modelling the decline in coronary heart disease deaths in England and Wales, 1981-2000: comparing contributions from primary prevention and secondary prevention. British Medical Journal 2005; 331:614.

119. Doll R et al. Mortality in relation to smoking: 50 years' observations on male British doctors. British Medical Journal 2004; 328:1519.

120. Ambrosonel CB, Harris CC. The development of molecular epidemiology to elucidate cancer risk and prognosis: a historical perspective. International Journal of Molecular Epidemiology and Genetics 2010; 1(2):84-91

121. Esselstyn Jr. CB. Updating a 12-year experience with arrest and reversal therapy for coronary heart disease. American Journal of Cardiology 1999; 84: 339-341.

122. Ornish D, for the Multicenter Lifestyle Demonstration Project Research Group. Avoiding revascularization with lifestyle changes: The multicenter lifestyle demonstration project. American Journal of Cardiology 1998; 82:72T-76T.

123. Heimlich HJ. Advantages and safety of clinical research, in Cohen M, Natelson N (eds). Facing the Challenge. Alexandria VA, Concern for Helping Animals in Israel, 1990, pp 123-135.

124. Savoy RL. History and future directions of human brain mapping and functional neuroimaging. Acta Psychologica 2001; 107:9-42.

125. Farwell MD, Pryma DA, Mankoff DA. PET/CT imaging in cancer: Current applications and future directions. Cancer 2014; 120:3433–3445.

126. Hill RB, Anderson RE. The Autopsy: Medical Practice and Public Policy. Boston, Butterworth, 1988.

127. Opie EL. Disease of the Pancreas. Philadelphia, JB Lippincott, 1910.

128. Barron M. The relation of the islets of Langerhans to diabetes with special reference to cases of pancreatic lithiasis. Surgery, Gynecology and Obstetrics 1920; 31:437-448.

129. Ahnen DJ. Are animal models of colon cancer relevant to human disease? Digestive Diseases & Sciences 1985; 30 (12 Suppl):103S-106S.

130. Pories SE, Ramchurren N, Summerhayes I, Steele G. Animal models for colon carcinogenesis. Archives of Surgery 1993; 128:647-653.

131. Hillier C, Bunton D. Could fresh human tissues play a key role in drug development. Alternatives to Laboratory Animals 2009; 37(suppl.):5-10.

132. Stevens C. Statement before the House Subcommittee on Labor, Health and Human Services, April 30, 1987.

133. Pihl A. UICC Study Group on chemosensitivity testing of human tumors. Problems – applications – future prospects. International Journal of Cancer 1986; 37:1-5.

134. Gura T. Systems for identifying new drugs are often faulty. Science 1997; 278:1041-1042.

135. Anon. Drug discovery screen adapts to change. Journal of the National Cancer Institute 1990; 82:1087.

136. Tsukamoto T. Animal disease models for drug screening: the elephant in the room? Drug Discov. Today 2016; 21:529-530.

137. Giri S, Bader A. A low-cost, high-quality new drug discovery process using patient-derived induced pluripotent stem cells. Drug Discovery Today 2015; 20:37-49.

138. Pound P, Bracken MB. Is animal research sufficiently evidence based to be a cornerstone of biomedical research? British Medical Journal 2014; 348:g3387.

139. Langley GR, Adcock IM, Busquet F, et al. Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations. Drug Discovery Today 2017;22:327-339.

140. Hendriksen CFM. Laboratory Animals in Vaccine Production and Control: Replacement, Reduction and Refinement. Boston, Kluwer Academic Pub, 1988.

141. Metz B, Hendricksen CF, Jiskoot W, Kersten GF. Reduction of animal use in human vaccine quality control: opportunities and problems. Vaccine 2002; 20:2411-30.

142. Hayflick L. The choice of the cell substrate for human virus vaccine production. Laboratory Practice 1970; 19:58-62.

143. Beale AJ. Use of tissue cultures for testing vaccines. Journal of the Royal Society of Medicine 1978; 71:681-686.

144. Hayflick L. Human virus vaccines: Why monkey cells? Science 1972; 176:183-184.



147. Lappin G, Noveck R, Burt T. Microdosing and drug development: past, present and future. Expert Opin Drug Metab Toxicol 2013; 9:817-834.

148. Yevale R, Khan N, Jagtap P, et al. A review on microdosing: Reduction in Cost & Time. International Journal of Pharmacy & Pharmaceutical Research 2016; 6:325-330.

149. Bazell RJ. Smoking dogs: Tobacco institute tries to discount cancer studies. Science 1970; 170:515.

150. Auerbach O, Hammond EC, Kirmian D, Garfinkel L. Effects of cigarette smoking on dogs II. Pulmonary neoplasms. Archives of Environmental Health 1970; 21:754-768.

151. Gluck JP, Kubacki SR. Animals in biomedical research: The undermining effect of the rhetoric of the besieged. Ethics and Behavior 1991; 2:157-173.

152. Weibers DO, Leaning J, White RG. Animal protection and medical science. The Lancet 1994; 343: 902-904.

153. Kaufman SR. Animal protection and medical science [letter]. The Lancet 1994; 343:1574.

154. Dunayer J. Censored: Faculty who oppose vivisection. Z Magazine, April 1993, pp. 57-60.

155. Arluke A. The ethical socialization of animal researchers. Lab Animal June 1994, pp 30-35.

156. Moore EJ. Animal Experiments [letter]. The Lancet 1986; 1 (8487): 975.

157. Phillips M. Savages, drunks and lab animals: The researcher's perception of pain. Society and Animals 1993; 1:61-81.

158. Howell DA. Antivivisection [letter]. British Medical Journal 1983; 286 (6381):1894.

159. Rowan AN. Is justification of animal research necessary? [letter]. Journal of the American Medical Association 1993; 269:1113-1114.

160. Buyukmihci NC. Consistency in treatment and moral concern. Journal of the American Veterinary Medical Association 1995; 206:477-480.

161. Archibald K. No need for monkeys [letter]. New Scientist  July 1, 2006, p 26.

162. Masson JM, McCarthy S. When Elephants Weep: The Emotional Lives of Animals. New York, Delacorte Press, 1995.

163. Bekoff M. The Smile of a Dolphin. New York, Discovery Books, 2000.

164. Balcombe, J. Second Nature: The Inner Lives of Animals. New York, Palgrave Macmillan, 2010.

165. Langford DJ et al. Social modulation of pain as evidence for empathy in mice. Science 2006; 312 (5782):1967-1970.

166. Masserman JH, Wechkin S, Terris W. 1964. ‘Altruistic’ behavior in rhesus monkeys. American Journal of Psychiatry 1964; 121:584–585.

167. Fouts RS. Next of Kin. New York, William Morrow, 1997.

168. Patterson F, Linden E. The Education of Koko. New York, Rinehart & Winston, 1991.

169. American Medical Association. AMA White Paper. Use of Animals in Biomedical Research: The Challenge and Response.1988.

170. U.S. Department of Agriculture. 2002 Farm Bill Amendment Section on Rats, Mice, and Birds.

171. Pew Research Center. Americans, Politics and Science Issues, Chapter 7: Opinion about the Use of Animals in Research. July 1, 2015.


Return to main menu

Table of Contents


Home  Info  Join